Search For
/
Stocks
Intraday Booster
Sector Booster
Stock Screener
Market Pulse
Screeners
More
Go Prime
My Plans
Privacy Policy
Contact
Refer & EarnScreenersMain
Stock Screener
Create Screener
Explore Screeners
Community ScreenersTrading Screeners
CandleSticks Screener
Top Gainers & Losers
Opening Range Breakout
Stock Screener AI
Stock Quality Scorecard
Overvalued StocksNewUndervalued StocksNewTechnical Screeners
NR4 Stocks
NR7 Stocks
Previous Day High Breakout
Previous Day Low Breakout
Previous Day Open Breakout
Bullish Crossover Stocks
Bearish Crossover Stocks
High Volume Shocker
VWAP Breakout Stocks
Range High Breakout
Range Low BreakoutMoreMarkets
Global Market Today
Global Indices
Indian Indices
NIfty TodaySmart Money
FII DII DataNew
FII Buying
NSE Insider Trading
SLB Stocks DataDerivatives
FnO Movements
NSE F&O Lot Size
Ban ListAnalysis & Calendars
Technical DashboardSector Booster
Sector AnalysisNew
Result Calendar
Economic Calendar
Suraksha Diagnostic
Small Cap•1,300 Employees•IPO 2024
Current Price
₹263.20
2.65 (1.02%)Updated
Today's Range
₹260.55
₹263.20
₹263.20
52 Week Range
52W Low₹240.00
52W High₹352.50
₹263.20
Downside9.67%
Upside33.93%
Price Chart
Compare with Peers
Historical Ratios
Track top 12 most important financial ratios
P/E Ratio: Price to Earnings - Most used valuation metric
Loading chart...
Analyzing Investment Quality
Processing 9 key metrics...
Key Metrics
Hover for details
Valuation
Market Cap
₹1,468.94 Cr
Market Cap
Total market value of companyP/E Ratio
44.52
P/E Ratio
Price to Earnings. Lower is generally better (<25 is good)P/B Ratio
6.36
P/B Ratio
Price to Book Value. <3 may indicate undervaluationEPS
₹6.34
EPS
Earnings Per Share. Higher and growing is positiveProfitability
ROE
-%
ROE
Return on Equity. >15% is good, >20% is excellentROCE
17.80%
ROCE
Return on Capital Employed. >15% is goodNet Margin
12.61%
Net Margin
Net profit as % of revenue. >10% is goodOperating Margin
-%
Operating Margin
Operating profit margin. >15% is goodGrowth
EPS Growth (5Y)
-%
EPS Growth (5Y)
5-year EPS growth. >15% is strongRevenue Growth (5Y)
-%
Revenue Growth (5Y)
5-year revenue growth. >10% is goodQtr Sales Growth
19.50%
Qtr Sales Growth
Quarter-over-quarter sales growthQtr Profit Growth
18.40%
Qtr Profit Growth
Quarter-over-quarter profit growthFinancial Health
Debt/Equity
0.42
Debt/Equity
Financial leverage. <1 is good, <0.5 is excellentBook Value
₹40.56
Book Value
Net asset value per shareDividend Yield
-%
Dividend Yield
Annual dividend as % of price. >2% is goodPromoter Holding
49.00%
Promoter Holding
Promoter stake. >50% shows confidenceGood
Average
Needs Attention
SWOT Analysis
Strengths
5 points- •Strong operating profit margin at 32.00% indicates efficient core operations.
- •Robust quarterly sales growth of 19.50% and profit growth of 18.40%.
Weaknesses
5 points- •High P/E ratio of 50.70 suggests potential overvaluation compared to earnings.
- •Zero dividend yield (0.00%) may not attract income-focused investors.
Opportunities
5 points- •Growing healthcare industry driven by rising health awareness and incomes.
- •Strong quarterly sales growth (19.50%) enables market share expansion.
Threats
4 points- •Highly competitive diagnostic industry may lead to pricing pressures.
- •Broader market volatility and recent stock decline pose price fluctuation risks.
Segment-wise Financial Analysis
Financial Results
Balance Sheet
Standalone • Annual • All amounts in ₹ Crores • CA Schedule III Format
No Balance Sheet Data Available
Standalone annual data is not available for this symbol.
Try switching to Consolidated view.
Shareholding Pattern
Loading shareholding data...
Company Insider Trading Activity
Recent Insider Transactions
| Insider Name | Transaction Date | Filing Date | Total Shares | Change | Price | Action |
|---|---|---|---|---|---|---|
Dr. Somnath Chatterjee | 13 Jun 2025 | 13 Jun 2025 | 26.07 L | 7,590 | ₹327.41 | BUY |
Corporate Action
Company Announcements
Technical Analysis & Indicators
Standard pivot points - most widely used
Pivot Points (CLASSIC)
| Level | Price | Distance | % Change |
|---|---|---|---|
| R4 | ₹269.38 | +₹6.18 | +2.35% |
| R3 | ₹266.73 | +₹3.53 | +1.34% |
| R2 | ₹264.97 | +₹1.77 | +0.67% |
| R1 | ₹264.08 | +₹0.88 | +0.34% |
| PIVOT | ₹262.32 | -0.88 | -0.34% |
| CURRENT | ₹263.20 | - | - |
| S1 | ₹256.13 | -₹7.07 | -2.68% |
| S2 | ₹258.78 | -₹4.42 | -1.68% |
| S3 | ₹259.67 | -₹3.53 | -1.34% |
| S4 | ₹261.43 | -₹1.77 | -0.67% |
CPR Levels
Support
Resistance
S4
N/A
S3
N/A
S2
N/A
S1
N/A
| CPR |
BC: N/AP: N/ATC: N/A
R1
N/A
R2
N/A
R3
N/A
R4
N/A
LTP: N/A
PDH: N/A
PDL: N/A
● Market Sentiment
is trading CPR, indicating
● CPR Width
CPR is
● Opening Range
Day's range: ~
● Price Position
Trading Inside opening range
Delivery Volume Analysis & Trading Activity
Latest Volume+10.1% vs avg
0.19L
(09 Mar 2026)Delivery %-5.6% vs avg
56.3%
(09 Mar 2026)Avg Volume (20D)20-day average
0.17L
(09 Feb - 09 Mar)Avg Delivery %Trend ↓
61.9%
(09 Feb - 09 Mar)Delivery % indicates the percentage of traded volume that resulted in actual delivery. Higher delivery % (>50%) suggests genuine buying interest and stronger hands.
Peer Comparison & Industry Benchmarking
Quick Compare
Largest by Market Cap
Dr Lal Pathlabs Ltd
24,046.66 ₹ Cr
Best Profit Growth
Thyrocare Technologies Ltd
79.90 %
Highest Dividend Yield
Thyrocare Technologies Ltd
1.66 %
Peer Comparison
| Company Name |
|---|
 Krsnaa Diagnostics Ltd |
 Dr Lal Pathlabs Ltd |
 Metropolis Healthcare Ltd |
 Thyrocare Technologies Ltd |
 Vijaya Diagnostic Centre Ltd |
About
Suraksha Diagnostic Ltd
Suraksha Diagnostic Limited is a prominent player in India's diagnostic healthcare industry, operating a network of diagnostic centers throughout the country. The company's core business revolves around providing a comprehensive suite of diagnostic testing services to patients and healthcare professionals. This wide-ranging portfolio contributes to their significant market presence and caters to a diverse client base.
A significant portion of Suraksha's revenue stems from its pathology testing services. This encompasses a broad spectrum of laboratory analyses, allowing for the detection and diagnosis of various medical conditions. The precise nature and extent of these pathology tests are not detailed in the provided information, but the breadth of services offered is clearly a key component of their business model.
Further enhancing its diagnostic capabilities, Suraksha offers a comprehensive range of radiology services. This includes advanced imaging techniques such as Magnetic Resonance Imaging (MRI), Computed Tomography (CT) scans, and Dual-Energy X-ray Absorptiometry (DEXA) scans. These technologies provide detailed internal images of the body, assisting in the diagnosis and monitoring of a variety of health issues. Their radiology offerings also extend to interventional ultrasonography, CT-guided biopsies, and standard X-ray imaging, illustrating a dedication to comprehensive and technologically advanced diagnostic practices.
In addition to its core diagnostic testing services, Suraksha also provides medical consultation services. While the specifics of these services are not detailed, the inclusion of this element suggests an integrated approach to patient care, potentially offering a more holistic and convenient experience by combining diagnostic testing with preliminary medical advice. This could involve consultations with physicians or other healthcare professionals associated with the company.
Established in 1992 and headquartered in Kolkata, India, Suraksha Diagnostic Limited has a long history of serving the healthcare needs of the Indian population. Its continued growth and expansion within the diagnostic services sector demonstrates its success in meeting the demand for accurate and timely diagnostic information.
COMPANY FACTS - SURAKSHA
Registered Address
Plot No. DG- 12/1, Action Area 1D, Premises No.: 02-0327, New Town, Rajarhat
Kolkata
WEST BENGAL
IN
Tel: 913366059750
Website:https://www.surakshanet.com/
Investor Relations:http://www.surakshanet.com/financials.php
Company Details
Group: Health Care Equipment & Services
Sector: Health Care
Industry: Health Care Providers & Services
Exchange: NATIONAL STOCK EXCHANGE OF INDIA
Employees: 1,300
IPO Date: 06/12/2024
MANAGEMENT - SURAKSHA
Ms. Ritu Mittal
Chief Executive Officer, Joint Managing Director, Executive Director
Mr. Ravindra K. S.
Group Chief Financial Officer
Ms. Mamta Jain
Compliance Officer, Company Secretary
Dr. Somnath Chatterjee
Joint Managing Director, Executive Director
Mr. Arun Sadhanandham
Nominee Director
Mr. Karan Verma
Director (Promoter)
Investor Questions Answered
Suraksha Diagnostic Ltd (SURAKSHA) Stock FAQs
Get answers to the most common questions about Suraksha Diagnostic Ltd stock price, fundamentals, financial metrics, and investment analysis
The current share price of Suraksha Diagnostic Ltd (SURAKSHA) is ₹263.2. Today, the stock has gained by ₹2.65 (1.02%), trading in a range of ₹260.55 to ₹263.2. The stock opened at ₹260.55 with a trading volume of 526 shares.
Suraksha Diagnostic Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹1,468.94 crores, P/E ratio of 44.52, ROE of 0.00%, and ROCE of 17.80%. The dividend yield stands at 0.00%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
The 52-week high price of Suraksha Diagnostic Ltd (SURAKSHA) is ₹352.5, while the 52-week low is ₹240. Currently trading at ₹263.2, the stock is 20.6% away from its 52-week low and 25.3% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
Whether to buy Suraksha Diagnostic Ltd stock at ₹263.2 depends on multiple factors. The stock is currently trading with a P/E ratio of 44.52 and P/B ratio of N/A. Today's performance shows a gain of 1.02%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
Suraksha Diagnostic Ltd offers a dividend yield of 0.00%, which means for every ₹100 invested at the current price of ₹263.2, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹2.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
Suraksha Diagnostic Ltd's key financial metrics include: P/E Ratio: 44.52, P/B Ratio: N/A, ROE: 0.00%, ROCE: 17.80%, Dividend Yield: 0.00%, EPS: ₹6.34, Book Value: ₹40.56, Debt-to-Equity: 0.42, and Current Ratio: N/A. The company's market cap stands at ₹1,468.94 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
Suraksha Diagnostic Ltd stock opened at ₹260.55 and is currently trading at ₹263.2, showing a gain of ₹2.65 (1.02%). The intraday high is ₹263.2 and low is ₹260.55. The trading volume stands at 526 shares, indicating moderate market participation today.
Suraksha Diagnostic Ltd has a Price-to-Earnings (P/E) ratio of 44.52, which means investors are willing to pay ₹44.52 for every ₹1 of earnings. With an EPS of ₹6.34, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
Suraksha Diagnostic Ltd has a market capitalization of ₹1,468.94 crores, making it a small-cap company. Market cap is calculated by multiplying the current stock price (₹263.2) by the total number of outstanding shares. This metric helps investors understand the company's size, stability, and investment risk profile.
Suraksha Diagnostic Ltd has a book value of ₹40.56 per share and a Price-to-Book (P/B) ratio of N/A. The current market price is ₹263.2, which is 548.9% above the book value. A P/B ratio below 1 may indicate undervaluation or asset quality concerns.
Suraksha Diagnostic Ltd has a Return on Equity (ROE) of 0.00% and Return on Capital Employed (ROCE) of 17.80%. ROE measures how efficiently the company generates profits from shareholders' equity, while ROCE indicates how well the company uses its capital to generate profits. These returns may need improvement for better profitability. Higher percentages generally indicate better financial performance.
Suraksha Diagnostic Ltd operates in the diversified sector and belongs to the general industry. The company competes with other players in this space and its performance is influenced by sector-specific trends, regulatory changes, and market dynamics. Understanding the sector helps investors assess growth potential, cyclical patterns, and industry-specific risks that may impact the stock's performance.
Suraksha Diagnostic Ltd has a debt-to-equity ratio of 0.42, which measures the company's financial leverage by comparing total debt to shareholders' equity. A low ratio suggests conservative financing with minimal debt. Lower ratios generally indicate lower financial risk, but optimal levels vary by industry.
Suraksha Diagnostic Ltd has an Earnings Per Share (EPS) of ₹6.34, which represents the company's profit allocated to each outstanding share. With a current stock price of ₹263.2 and P/E ratio of 44.52, investors are paying 44.52 times the annual earnings per share. The company may need to improve its earnings performance. Track EPS growth over quarters to assess earnings momentum.
Suraksha Diagnostic Ltd has reported a sales growth of N/A% and profit growth of N/A%. The company may be facing growth challenges or operating in a mature market. Consistent growth over multiple quarters is a positive indicator for long-term investors. Compare these growth rates with industry peers for better perspective.
Suraksha Diagnostic Ltd has a current ratio of N/A, which measures the company's ability to pay short-term obligations with current assets. A ratio below 1 may indicate potential liquidity concerns. This metric is crucial for assessing the company's working capital management and financial safety.
To analyze Suraksha Diagnostic Ltd stock, consider: 1) Fundamental Analysis - Review P/E (44.52), ROE (0.00%), debt-to-equity (0.42), and growth rates. 2) Technical Analysis - Check 52-week range (₹240.00 - ₹352.50), moving averages, and chart patterns. 3) Valuation - Compare current price (₹263.20) with book value (₹40.56) and industry peers. 4) Financial Health - Assess current ratio (N/A) and cash flows. 5) Growth Prospects - Evaluate sales growth (N/A%) and profit growth (N/A%). Always diversify and consult a financial advisor.
The face value (or par value) of Suraksha Diagnostic Ltd share is ₹2.00. Face value is the nominal value of a share as stated in the company's charter and is used for accounting purposes and calculating dividends. The current market price of ₹263.2 is 13060x the face value. Face value remains constant unless the company undergoes a stock split or bonus issue, while market price fluctuates based on demand and supply.
Investing in Suraksha Diagnostic Ltd carries several risks: 1) Market Risk - Stock price volatility (52-week range: ₹240.00 - ₹352.50). 2) Business Risk - Industry-specific challenges in the sector. 3) Financial Risk - Debt-to-equity ratio of 0.42 indicates leverage. 4) Liquidity Risk - Based on trading volume of 526 shares. 5) Valuation Risk - P/E of 44.52 may indicate over/undervaluation. 6) Economic Risk - Macroeconomic factors affecting the industry. Diversify your portfolio and invest only what you can afford to lose.
Suraksha Diagnostic Ltd operates in the industry with key metrics: P/E ratio of 44.52, ROE of 0.00%, market cap of ₹1,468.94 crores, and dividend yield of 0.00%. To make an informed comparison, analyze these metrics against industry peers considering factors like revenue growth (N/A%), profit margins, debt levels (D/E: 0.42), and market position. Use our peer comparison tool on this page to see detailed side-by-side analysis with competitors.
Target prices for Suraksha Diagnostic Ltd vary among analysts and depend on multiple factors including earnings projections, industry trends, and market conditions. The stock is currently trading at ₹263.2, with a 52-week range of ₹240.00 to ₹352.50. Based on fundamentals like P/E (44.52), ROE (0.00%), and growth rates, analysts may have different target prices. Always refer to recent research reports from reputed brokerages and make decisions based on your own analysis and risk appetite.
Consider selling Suraksha Diagnostic Ltd stock when: 1) Target Price Achieved - If the stock reaches your predetermined target from current ₹263.20. 2) Fundamental Deterioration - Declining ROE (currently 0.00%), increasing debt (D/E: 0.42), or falling growth rates. 3) Better Opportunities - Finding stocks with superior risk-reward ratios. 4) Portfolio Rebalancing - When the stock becomes overweight in your portfolio. 5) Changed Investment Thesis - If reasons for buying no longer hold. 6) Stop Loss - If price falls below your risk threshold. Always base decisions on thorough analysis rather than emotions.
Tax implications for Suraksha Diagnostic Ltd stock investments: 1) Short-term Capital Gains (STCG) - If sold within 1 year, gains taxed at 15% plus cess. 2) Long-term Capital Gains (LTCG) - If held over 1 year, gains above ₹1 lakh taxed at 10% without indexation. 3) Dividend Income - Dividends (current yield: 0.00%) are taxable as per your income tax slab. 4) Securities Transaction Tax (STT) - Applicable on both buy and sell transactions. 5) Intraday Trading - Treated as speculative income, taxed as per slab. Tax laws change periodically, so consult a tax advisor for personalized guidance and latest regulations.
Menu